|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 860 WINTER STREET |
Address2 |
|
City | WALTHAM |
State | MA |
Zip Code | 02451 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 23975-12
|
||||||||
|
6. House ID# 319670000
|
TYPE OF REPORT | 8. Year | 2015 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Corinne Broderick, Executive Vice President |
Date | 1/19/2016 3:46:31 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
PL 114 - 20 - the Medicare Access and Chip Reauthorization Act - SGR repeal, CHIP reauthorization, Community Health Center Reauthorization - comments on regulations re: quality measurements, technical support for small businesses, MIPS, APMS
HR 293 - the Protect Continuing Physician Education Act and Patient Care Act - regulations implementing the Sunshine Act
HR 6 - 21st Century Cures - provisions impacting Sunshine Act
S 320 - Medical Innovation Act - NIH funding
Opioid Addiction issues
S. 1455 - TREAT ACT, Recovery Enhancement for Addiction Act
S. 1641 - The Jason Simcakoski Memorial Opioid Safety Act
s. 480 - Reauthorization of NASPER - The National All Schedules Prescription Electronic Reporting Act - No specific bill
S. 1392 Safer Prescribing of Controlled Substances Act
HR 2085/S. 1134 - Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015
HR 1462/S 799 - Protecting our Infants Act of 2015 - PL 114-91
Partial Fill legislation - no specific bill
Funding for demonstration projects for access to pain specialists - no specific bill
DEA - change/classification of regulations regarding partial fill of prescriptions
E Prescribing - no specific bill
S. 524 - Comprehensive Addiction and Recovery Act of 2015
S. 1134 - Heroin and Prescription Opioid Abuse Education and Enforcement Act
Draft CDC Guideline for Prescribing Opioids for Chronic Pain
Prescriber Education on the VA System draft legislation
Prescription Drug Pricing - no specific bill
Direct to Consumer Advertising - no specific bill
Negotiating Prescription Drug Prices for Medicare and Medicaid - no specific bill
Access to medically tailored food for low income people - no specific bill
S 139/HR 209 - the Ensuring Access to Clinical Trials Act of 2015 - PL 114-63
Meaningful Use and Electronic Medical Records - HR 3309 - Future Flexibility on HIT Reporting and Advancing Interoperability Act
Opposition to Meaningful Use Stage III Rules
HR 3940 - Meaningful Use Hardship Relief Act - PL 114-115
HR 2568 - Fair Medical Audits Act of 2015
DEA Reclassification of marijuana to allow scientific research and study
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Natl Institutes of Health (NIH), Drug Enforcement Administration (DEA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexandra |
Calcagno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
PL 114 - 20 - the Medicare Access and Chip Reauthorization Act - SGR repeal, CHIP reauthorization, Community Health Center Reauthorization - comments on regulations re: quality measurements, technical support for small businesses, MIPS, APMS
HR 293 - the Protect Continuing Physician Education Act and Patient Care Act - regulations implementing the Sunshine Act
HR 6 - 21st Century Cures - provisions impacting Sunshine Act
Meaningful Use and Electronic Medical Records - HR 3309 - Future Flexibility on HIT Reporting and Advancing Interoperability Act
Opposition to Meaningful Use Stage III Rules
HR 3940 - Meaningful Use Hardship Relief Act - PL 114-115
HR 2568 - Fair Medical Audits Act of 2015
Prescription Drug Pricing - negotiating drug prices for Medicare and Medicaid - no specific bill
HR 2568 - Fair Medical Audits
HR 209/S. 1391 - Ensuring Access to Clinical Trials Act of 2015 - PL 114-63
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexandra |
Calcagno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ALC
16. Specific lobbying issues
Opioid Addiction issues
S. 1455 - TREAT ACT, Recovery Enhancement for Addiction Act
S. 1641 - The Jason Simcakoski Memorial Opioid Safety Act
s. 480 - Reauthorization of NASPER - The National All Schedules Prescription Electronic Reporting Act - No specific bill
S. 1392 Safer Prescribing of Controlled Substances Act
HR 2085/S. 1134 - Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015
HR 1462/S 799 - Protecting our Infants Act of 2015 - PL - 114-91
Partial Fill legislation - no specific bill
Funding for demonstration projects for access to pain specialists - no specific bill
DEA - change/classification of regulations regarding partial fill of prescriptions
E Prescribing - no specific bill
S. 524 - Comprehensive Addiction and Recovery Act of 2015
S. 1134 - Heroin and Prescription Opioid Abuse Education and Enforcement Act
Draft CDC Guideline for Prescribing Opioids for Chronic Pain
Prescriber Education on the VA System draft legislation
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Drug Enforcement Administration (DEA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexandra |
Calcagno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
S 320 - Medical Innovation Act - NIH funding
DEA Reclassification of marijuana to allow scientific research and study
Prescription Drug Pricing - no specific bill
Direct to Consumer Advertising - no specific bill
Negotiating Prescription Drug Prices for Medicare and Medicaid - no specific bill
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Drug Enforcement Administration (DEA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexandra |
Calcagno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |